COST EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS

被引：0
|
作者：
Kip, M. [1 ]
van den Bosch, M. [2 ,3 ]
Fischer, K. [4 ]
Tamminga, R. [5 ]
Lepage-Nefkens, I [1 ]
机构：
[1] PANAXEA, Enschede, Netherlands
[2] Bayer, Mijdrecht, Netherlands
[3] Univ Med Ctr Utrecht, Van Creveldkliniek, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[5] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1687
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY57
引用
收藏
页码：A531 / A531
页数：1
相关论文
共 50 条
  • [1] Evaluating the treatment of severe haemophilia A using cost-effectiveness measures in primary prophylaxis
    Axelsen, F.
    Miners, A.
    HAEMOPHILIA, 2011, 17 (02) : 364 - 365
  • [2] Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A
    Miners, A.
    HAEMOPHILIA, 2009, 15 (04) : 881 - 887
  • [3] Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A
    Hay, JW
    Ernst, RL
    Kessler, CM
    HAEMOPHILIA, 1999, 5 (03) : 191 - 202
  • [4] Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness
    Schlenkrich, S.
    Schubert, C.
    HAMOSTASEOLOGIE, 2013, 33 (03): : 241 - 244
  • [5] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
    Pipe, S. W.
    Collins, P.
    Dhalluin, C.
    Kenet, G.
    Schmitt, C.
    Buri, M.
    Jimenez-Yuste, V.
    Peyvandi, F.
    Young, G.
    Oldenburg, J.
    Mancuso, M. E.
    Kavakli, K.
    Kiialainen, A.
    Niggli, M.
    Chang, T.
    Lehle, M.
    Fijnvandraat, K.
    HAEMOPHILIA, 2024, 30 : 24 - 25
  • [6] Optimizing efficacy of factor VIII prophylaxis for severe haemophilia A
    Fischer, K.
    HAEMOPHILIA, 2011, 17 : 9 - 15
  • [7] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [8] Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A
    Iannazzo, Sergio
    Cortesi, Paolo A.
    Crea, Roberto
    Steinitz, Katharina
    Mantovani, Lorenzo G.
    Gringeri, Alessandro
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (06) : 425 - 430
  • [9] Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia
    Miners, AH
    Lee, CA
    HAEMOPHILIA, 2004, 10 : 58 - 62
  • [10] Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
    Carlsson, M
    Berntorp, E
    Bjorkman, S
    Lethagen, S
    Ljung, R
    HAEMOPHILIA, 1997, 3 (02) : 96 - 101
12345